Tool-First Data Governance Creates Activity Without Impact, Finds Info-Tech Research Group

NEWS PROVIDED BY

Info-Tech Research Group

Aug 31, 2026, 17:54 ET

SHARE THIS ARTICLE

Expanding AI initiatives are increasing pressure on organizations to provide trustworthy data, but many governance programs remain fragmented or focused on management mechanisms. Info-Tech Research Group's Activate Data Governance blueprint provides data and IT leaders with a four-phase methodology to clarify decision authority, establish guardrails, and embed governance into how the organization operates.

ARLINGTON, Va., Aug. 31, 2026 /PRNewswire/ -- Every organization that uses data already has some form of data governance because decisions are being made about how data is defined, accessed, shared, and used. According to Info-Tech Research Group, the problem is that these decisions are often fragmented across risk, privacy, finance, product, and legacy data management practices. Without a consistent framework, teams may resolve the same questions differently while investments in catalogs, glossaries, and technology create activity without measurable impact.

Info-Tech’s Four-Phase Framework to Activate Data Governance

To help organizations establish a consistent system for data-related decisions, Info-Tech's Activate Data Governance blueprint explains how to identify the decisions that matter, direct them to people with the appropriate authority and expertise, codify the outcomes into guardrails, and integrate governance into existing organizational structures.

"Data leaders often reach for glossaries, catalogs, and quality tools first because those mechanisms feel actionable. The problem is that tools cannot decide what 'trusted' means, who has authority, or which trade-offs are acceptable," says Nysa Zaran, research director at Info-Tech Research Group. "Those are business judgments. Governance starts when the right people make them and turn the outcomes into guardrails the organization can apply."

According to Info-Tech's Future of IT 2026 Survey, 72.5% of organizations are currently invested in data management solutions and plan to increase that investment. Improving data governance also ranked as the leading data priority both for supporting AI goals, cited by 30%, and outside AI, cited by 40%. The firm emphasizes that the findings point to a disconnect between investment in management solutions and the unresolved governance decisions needed to guide them.

Key Data Governance Pitfalls 

Info-Tech's blueprint identifies three common misconceptions that can derail data governance efforts:

Mistaking governance for management: Beginning with tools, catalogs, quality mechanisms, and documentation before determining which decisions must be made and who has the authority to make them.

Oversimplifying ownership: Assigning a single owner to data that spans multiple domains and functions without accounting for shared value, risk, and decision-making responsibilities.

Misinterpreting activation: Equating activation with assigning management tasks while decisions tied to value, risk, and acceptable use remain unresolved.

Info-Tech's Four-Phase Framework to Activate Data Governance

The Activate Data Governance blueprint recommends that organizations activate data governance through the following four phases:

Phase 1: Define the Decisions the Organization Needs to Make. Identify governance drivers, connect data issues and risks to organizational objectives, and articulate the purpose of the governance program.

Phase 2: Define the Decision-Making Framework. Align governance with existing organizational structures, clarify roles and membership, and establish processes to raise and escalate issues.

Phase 3: Establish Critical Guardrails. Define governing principles, foundational policies and processes, performance measures, and the organization's Data Governance Charter.

Phase 4: Activate Data Governance Within the Organization. Prepare Day 1 Agendas, secure strategic approval, host initial governance meetings, and establish an ongoing cycle for monitoring and validating guardrails.

Info-Tech's Activate Data Governance blueprint is supported by templates and tools that help organizations apply the methodology, including the Activate Data Governance Decision Log, Activate Data Governance Handbook, Data Governance Day 1 Agenda, Activate Data Governance Workbook, Data Governance Charter Template, and Data Governance Policies Package.

For exclusive and timely commentary from Info-Tech's experts, including Nysa Zaran, and access to the complete Activate Data Governance blueprint, please contact pr@infotech.com.

About Info-Tech Research Group

Info-Tech Research Group is the "get things done" partner for over 30,000 IT, HR, and marketing leaders worldwide. The fastest growing research and advisory firm, Info-Tech enables leaders to make well-informed decisions and transform their organizations through AI, strategic foresight, step-by-step methodologies, practical tools, industry-leading advisory, and training programs. For nearly 30 years, tens of thousands of private and public organizations have trusted Info-Tech to lead their most important initiatives through periods of change and deliver outcomes that truly matter.

To learn more about Info-Tech's HR research and advisory services, visit McLean & Company, and for data-driven software buying insights and vendor evaluations, visit the firm's SoftwareReviews platform.

Media professionals can register for unrestricted access to research across IT, HR, and software, and hundreds of industry analysts through the firm's Media Insiders program. To gain access, contact pr@infotech.com.

For information about Info-Tech Research Group or to access the latest research, visit infotech.com and connect via LinkedIn and X.

SOURCE Info-Tech Research Group

21%

more press release views with 

Request a Demo

Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering

NEWS PROVIDED BY

Kazia Therapeutics Limited

Aug 31, 2026, 17:58 ET

SHARE THIS ARTICLE

Company to host a corporate update call Tuesday, September 1st at 8:00am ET

SYDNEY, Aug. 31, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the closing of its previously announced oversubscribed, tranched registered public offering (the "Offering") generating approximately $40 million in upfront gross proceeds. Both clinical milestone-linked warrant tranches were priced at premiums to the $15.50 offering price, with exercise prices of $17.825 per ADS, a 15% premium, tied to the Company's Stage IV triple-negative breast cancer ("TNBC") data readout, and $19.375 per ADS, a 25% premium, tied to the Company's HR+/HER2- breast cancer data readout. If all milestone-linked warrants are exercised in full, the Offering would provide Kazia with approximately $80 million in additional gross proceeds, for total potential gross proceeds of approximately $120 million.

The Offering consisted of (i) 2,580,000 American Depositary Shares ("ADSs"), each representing five hundred (500) ordinary shares of the Company, no par value per share, or in lieu of ADSs to certain investors, pre-funded warrants to purchase ADSs, (ii) accompanying Series A Warrants to purchase up to 2,243,478 ADSs (or pre-funded warrants in lieu thereof), exercisable immediately at a purchase price of $17.825 per ADS, expiring upon the earlier of 30 days following the Company's Stage IV triple-negative breast cancer (TNBC) data readout, expected in the second half of 2027, or the five-year anniversary of issuance, and (iii) accompanying Series B Warrants to purchase up to 2,064,000 ADSs (or pre-funded warrants in lieu thereof), exercisable immediately at a purchase price of $19.375 per ADS, expiring upon the earlier of 30 days following the Company's HR+/HER2- data readout, expected in the first half of 2028, or the five-year anniversary of issuance. All securities in the Offering were sold by Kazia.

The combined public offering price was $15.50 per ADS together with its accompanying Series A and Series B Warrants, and $15.4999 (equal to the combined public offering price per ADS and accompanying warrants less $0.0001) for each pre-funded warrant together with its accompanying Series A and Series B Warrants. Gross proceeds to Kazia at closing were approximately $40 million, before deducting underwriting discounts, commissions, and offering expenses.

The Offering included participation from new and existing institutional investors, including ADAR1 Capital Management, Columbia Threadneedle Investments, Lynx1 Capital Management, Marshall Wace, and Pointillist Family Office.

Leerink Partners and Guggenheim Securities acted as joint bookrunning managers, BTIG and Needham & Company acted as lead managers, and Laidlaw & Company (UK) Ltd. acted as co-manager for the Offering.

Kazia intends to use the net proceeds from the Offering primarily to fund clinical development of paxalisib, including ongoing and planned studies in triple-negative breast cancer, HR+/HER2- breast cancer, and pMMR colorectal cancer, as well as for working capital and general corporate purposes.

Corporate Update Call

Kazia Therapeutics will host a corporate update conference call on Tuesday, September 1, 2026, at 8:00am ET. A link to the webcast of the conference call will be available on the Kazia website at https://www.kaziatx.com/investors/news-and-events/ir-calendar or click here. The conference call can also be accessed by dialing 1-877-407-4018 (U.S.) or 1-201-689-8471 (international), using Conference ID: 13762519.

About Kazia Therapeutics

Kazia Therapeutics (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. The Company's lead asset, paxalisib, is an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of over 15 clinical trials. A completed Phase 2/3 study in glioblastoma (GBM AGILE) was reported in 2024, and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy. Additionally, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020 and for atypical teratoid/rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class intracellular PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, as well as MSETC, a potentially first-in-class SETDB1 inhibitor program intended to restore immune signaling in tumors that have become resistant to immunotherapy, including checkpoint inhibitors. Both programs are currently in preclinical development. For more information, please visit www.kaziatx.com or follow us on X @KaziaTx.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements regarding the Offering and the potential gross proceeds therefrom, including the exercise of the Series A Warrants and Series B Warrants; the Company's ability to achieve clinical milestones, including the Stage IV TNBC and HR+/HER2- data readouts that may trigger warrant exercise periods; the Company's intended use of proceeds; and the Company's plans for clinical development of paxalisib. Forward-looking statements are generally identified by words such as "anticipates," "believes," "expects," "intends," "plans," "may," "will," "could," "should," "estimates," "projects," "potential," and similar expressions. These forward-looking statements are based on management's current expectations and assumptions as of the date of this press release and are subject to significant risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied.

Such risks and uncertainties include, but are not limited to: the Company's ability to complete the Offering; the Company's ability to achieve clinical milestones, including the Stage IV TNBC and HR+/HER2- data readouts that trigger warrant exercise periods; risks associated with the conduct of clinical trials and regulatory approvals; volatility in the price of the Company's ADSs and warrants; general economic and market conditions; and the Company's ability to maintain compliance with NASDAQ listing requirements.

For a more complete discussion of risks and uncertainties, please refer to the Company's filings with the SEC, including the "Risk Factors" section of the Company's most recent Annual Report on Form 20-F. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements are qualified in their entirety by this cautionary statement.

SOURCE Kazia Therapeutics Limited

21%

more press release views with 

Request a Demo

CHARTER ANNOUNCES CHIEF FINANCIAL OFFICER TRANSITION

NEWS PROVIDED BY

Charter Communications, Inc.

Aug 31, 2026, 16:15 ET

SHARE THIS ARTICLE

STAMFORD, Conn., Aug. 31, 2026 /PRNewswire/ -- Charter Communications (NASDAQ: CHTR) today announced that Jessica Fischer will step down from her current position as the Company's Chief Financial Officer on October 15, to relocate for another professional opportunity. The Company will begin a comprehensive search for her replacement immediately.

Charter also named Kevin Howard, currently Executive Vice President and Chief Accounting Officer & Controller, to the position of interim Chief Financial Officer effective October 15. Mr. Howard will continue to work closely with Ms. Fischer to support ongoing financial operations and ensure a seamless leadership transition.

"I first met Jessica more than 15 years ago and actively recruited her to join our team at Charter," said Chris Winfrey, President & CEO, Charter Communications. "Since joining Charter nearly 10 years ago, and becoming our CFO in 2021, she has been a key part of our executive team. I am very proud of our work together and grateful for her many contributions in making Spectrum the leading broadband and video company in the country."

"It has been a privilege to be part of Charter's growth over the past decade," said Ms. Fischer. "I have learned so much from Chris and this team and am grateful for the opportunity and trust they placed in me to lead Charter's financial operation."

Mr. Howard brings over two decades of financial leadership to his role as Charter's Executive Vice President and Chief Accounting Officer & Controller, overseeing accounting, tax, financial reporting, and ERP operations. He has led the financial integration of a number of Charter's major transactions, including the acquisitions of Bresnan, Time Warner Cable, Bright House Networks and Cox Communications. He previously served as Charter's interim CFO in 2010.

Charter has not changed any of its previously provided financial outlook or financial policy.

About Charter 

Charter Communications, Inc. (NASDAQ: CHTR) is the leading broadband and video company in the nation and the fastest growing mobile provider in its footprint, with services available to more than 70 million homes and small to large businesses across 45 states through its Spectrum brand. Founded in 1993, Charter has evolved from providing cable TV to streaming, and from high-speed Internet to a converged broadband, WiFi and mobile experience. Over the Spectrum Fiber Broadband Network and supported by our 100% U.S.-based employees, the Company offers Seamless Connectivity and Entertainment with Spectrum Internet®, Mobile, TV and Voice products.

More information can be found at corporate.charter.com.

SOURCE Charter Communications, Inc.

21%

more press release views with 

Request a Demo

Cisco to Participate in September Events with the Financial Community

NEWS PROVIDED BY

Cisco Systems, Inc.

Aug 31, 2026, 16:30 ET

SHARE THIS ARTICLE

SAN JOSE, Calif., Aug. 31, 2026 /PRNewswire/ -- Cisco (NASDAQ: CSCO) will participate in the following events with the financial community in September:

Goldman Sachs Communacopia + Technology Conference 2026, San Francisco

Tuesday, September 8, 2026

Investor Meetings & Fireside Chat at 11:30am PDT

(Webcast & registration will be made available on investor.cisco.com)

Cisco Representatives:

Mark Patterson, EVP & Chief Financial Officer

Jeetu Patel, President & Chief Product Officer  

Cisco Investor Relations

Citi 2026 Global TMT Conference, New York

Thursday, September 10, 2026

Investor Meetings & Fireside Chat at 9:35am PDT

(Webcast & registration will be made available on investor.cisco.com)

Cisco Representatives:

Sami Badri, SVP, Investor Relations & Strategic Finance

Truist Technology Symposium, New York

Tuesday, September 15, 2026

Investor Meetings Only

Cisco Representatives:

Sami Badri, SVP, Investor Relations & Strategic Finance

Piper Sandler 2026 Tech Conference, Nashville  

Wednesday, September 16, 2026

Investor Meetings Only

Cisco Representatives:

Sami Badri, SVP, Investor Relations & Strategic Finance

European Conference on Optical Communication (ECOC) 2026, Málaga, Spain

Monday, September 21, 2026

Investor meetings only

Cisco Representatives:

Tom Williams, VP Product Management, Acacia

Lorenzo Ghioni, VP Product Management, Optical Systems

Ron Horan, VP, Product Management, Client Optics Group

Emily Hunt, Director, Investor Relations

JP Morgan US All Stars Conference, London

Wednesday, September 23, 2026

Investor Meetings Only

Cisco Representatives:

Emily Hunt, Director, Investor Relations

About Cisco

Cisco (NASDAQ: CSCO) is the worldwide technology leader that is revolutionizing the way organizations connect and protect in the AI era. For more than 40 years, Cisco has securely connected the world. With its industry leading AI-powered solutions and services, Cisco enables its customers, partners and communities to unlock innovation, enhance productivity and strengthen digital resilience. With purpose at its core, Cisco remains committed to creating a more connected and inclusive future for all. Discover more on The Newsroom and follow us on X at @Cisco.

SOURCE Cisco Systems, Inc.

21%

more press release views with 

Request a Demo

UCB Comes to Agreement with U.S. Government to Lower the Cost of Medicine and Strengthen U.S. Manufacturing

NEWS PROVIDED BY

UCB

Aug 31, 2026, 16:30 ET

SHARE THIS ARTICLE

Ensuring patients have access to the medicines they need through long-term commitment to patients and scientific innovation

Building on long-standing U.S. presence, expanded investments in research, manufacturing infrastructure, and highly skilled jobs will strengthen economic growth

For nearly a century, UCB's investment in differentiated science has fueled a robust pipeline of innovation, advancing the breakthroughs of tomorrow

BRUSSELS and ATLANTA, Aug. 31, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company focused on improving the lives of people living with severe diseases, today announced that they've come to an agreement with the U.S. government that will continue to support patient access to important medicines while enabling significant investment in the research, development, and manufacturing of medicines for people living with severe neurological and immunological diseases.

"At UCB, we are guided by a clear purpose: to create value for patients now and into the future," said UCB's CEO Jean-Christophe Tellier: "Working with the U.S. Government reflects our commitment to support access to medicines for people who need them, while continuing to advance the science and innovation that can make a meaningful difference for people living with severe diseases. These priorities, and our contribution to the United States through research, manufacturing, and highly skilled jobs, are essential to our long-term commitment to patients."

UCB will:

Take a more balanced pricing approach for future medicine launches across developed nations

Participate in the Government's GENEROUS program

Continue its onshore manufacturing investment to serve patients with medicines made in the United States

Earlier this year, UCB committed to expanding its U.S. manufacturing footprint, anchored by a new biologics manufacturing facility in Georgia — the largest manufacturing investment in the company's history. The facility is expected to generate approximately $5 billion in U.S. economic impact and create approximately 330+ permanent, highly skilled jobs, helping to strengthen domestic biopharmaceutical manufacturing and supply chain resilience of recently approved and future pipeline medicines in immunology and rare disease.

The agreement supports UCB's ability to execute our strategy and continue delivering innovative medicines to patients in the U.S. and around the world. As a result, UCB will not be subject to Section 232 Pharmaceutical tariffs on all current products or future pricing mandates. Specific terms remain confidential.

Separately, UCB will donate Keppra® (levetiracetam), which is recognized by the FDA as an Essential Medicine, active pharmaceutical ingredient (API) and tablets to the Administration for Strategic Preparedness and Response's (ASPR) National Stockpile. This donation will help strengthen the resilience of the U.S. essential medicines supply chain, support national preparedness efforts, and help safeguard access to a critical treatment for patients when it is needed most.

About UCB in the U.S.

UCB has maintained a significant U.S. presence for decades, including its U.S. headquarters and eight offices across six communities in California, Georgia, Massachusetts, North Carolina, Washington, and Washington, D.C. With nearly 2,000 U.S. employees focused on research, development, and commercial operations across the country, UCB is adding a U.S. biomanufacturing campus in Georgia, which will create 330+ new, highly skilled jobs. UCB has increased its U.S. workforce by more than 70% since 2017, with over 25% of U.S. employees dedicated to R&D. Over the last decade, UCB has made significant investments in U.S. companies through acquisitions and partnerships and has achieved 15 FDA approvals, advancing innovation, supporting high-quality jobs, and delivering meaningful progress for patients.

About UCB 

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of € 7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB).

For further information, contact UCB:

Investor Relations

Yvonne Naughton

T +44-750-057 0135

email yvonne.naughton@ucb.com  

Sahar Yazdian

T +32.2.559.91.37

email sahar.yazdian@ucb.com  

Corporate Communications

Laurent Schots

T +32.2.559.92.64

Email laurent.schots@ucb.com

U.S. Communications

Erica Puntel

T 404.938.5359

Email erica.puntel@ucb.com

Forward looking statements 

This document contains forward-looking statements, including, without limitation, statements containing the words "potential", "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document.

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of UCB's information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in laws and/or rules pertaining to tax and duties or the administration of such laws and/or rules, and hiring, retention and compliance of employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.

UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

SOURCE UCB

21%

more press release views with 

Request a Demo

Dibyava Ghosh appointed CEO as Robertshaw accelerates growth and innovation in advanced flow control solutions

NEWS PROVIDED BY

Robertshaw

Aug 31, 2026, 16:43 ET

SHARE THIS ARTICLE

ITASCA, Ill., Aug. 31, 2026 /PRNewswire/ -- Robertshaw, a global leader in thermal and advanced flow control solutions, announced that its Board of Directors has approved the appointment of Dibyava Ghosh as Chief Executive Officer. Ghosh was originally appointed President and Interim CEO in May 2026.

Ghosh brings a proven track record of driving market-beating growth and operational excellence across complex global industrial businesses. Recognized for her expertise in multi-site global P&L management, portfolio scale-up, and localized supply chain integration, she has consistently led large organizations through high-stakes product launches and rapid value creation. Her core strengths span dynamic commercial positioning, strategic execution, accretive portfolio integration, and leading high-performance teams across global engineering and manufacturing footprints.

Prior to joining Robertshaw, Ghosh demonstrated these strategic leadership capabilities as President of CPM, President/CEO of Hill & Smith Inc., and Global Managing Director for IMI PLC's Industrial Automation sector. She also spent nearly 13 years in key division leadership roles at Parker Hannifin, following strategic business planning leadership roles at Motorola Solutions.

"It is an honor to lead Robertshaw at such a pivotal moment in our history," said Ghosh. "Having spent the last few months working alongside our talented teams across the globe, I am deeply inspired by our rich legacy of engineering excellence and the immense growth opportunities ahead. My focus is on accelerating our innovation pipeline, strengthening our customer partnerships, and driving operational performance as we engineer the next generation of flow and control solutions."

With a history of innovation spanning over 125 years, Robertshaw is a global designer, manufacturer, and supplier of primary flow control components, systems, and solutions for residential, commercial, HVAC, and transportation markets. Headquartered in Itasca, Illinois, Robertshaw operates engineering, R&D, and manufacturing facilities across the globe. For additional information, visit http://www.robertshaw.com.

Media Contact:

Katie Kretschmar

Sr. Marketing Manager, Robertshaw

katie.kretschmar@robertshaw.com

SOURCE Robertshaw

21%

more press release views with 

Request a Demo

Cango Inc. Reports Second Quarter 2026 Unaudited Financial Results

NEWS PROVIDED BY

Cango Inc.

Aug 31, 2026, 17:00 ET

SHARE THIS ARTICLE

DALLAS, Aug. 31, 2026 /PRNewswire/ -- Cango Inc. (NYSE: CANG) ("Cango" or the "Company"), a leading Bitcoin miner leveraging its global operations to develop an integrated energy and AI compute platform, today announced its unaudited financial results for the second quarter ended June 30, 2026.

Second Quarter of 2026 Financial and Operational Highlights

Financial Performance: Even as the broader mining industry weighed on revenue, the Company continued to advance its diversification strategy through EcoHash's commercial progress and disciplined cost management. In the second quarter of 2026, the Company generated total revenue of US$50.8 million, primarily driven by US$47.4 million from its Bitcoin mining business. The Company reported a net loss of US$81.6 million, primarily driven by non-cash impairment and disposal losses on the mining machines.  As of the end of the period, the Company held 1,056 Bitcoins as digital asset reserves, with long-term debt of US$31.2 million, reflecting an improved balance sheet structure.

Mining Operations and Costs: To reinforce its disciplined cost management, the Company continued to actively right-size its mining operations, disposing of machines with lower marginal efficiency and partially executing a leasing model. Total operating hashrate reached 27.58 EH/s, comprising 19.84 EH/s of self-mining capacity and 7.74 EH/s of leased hashrate capacity as of June 30, 2026. During the quarter, the Company mined 656 Bitcoins. The improved fleet mix and disciplined execution drove an approximately 5% sequential reduction in average cash cost per Bitcoin, which declined to US$73,313. The Company also started to selectively execute a hedging strategy to mitigate the impact of price volatility on operations.

Mr. Paul Yu, Chief Executive Officer of Cango, said, "In our Bitcoin mining business, we continue to focus on unit economics rather than scale.  At the same time, we continued to deliver on our AI modular build at our LN mining site. The Georgia site completed conversion in early July and the infrastructure is now capable of supporting up to 3 megawatts, with scope for future expansion. Container units have been delivered and installed on site, and GPU hardware has been procured and is arriving in staged batches to support a phased ramp-up. In the future, we intend to pursue two business models. The first is bare-metal GPU hosting, using our infrastructure to offer a standardized deployment environment. The second is colocation, intended to enhance overall infrastructure utilization. Our Georgia site is in the process of onboarding customers, with revenue expected to be recognized in the third quarter. To support customers who require proximity-based deployment, we have begun to operate test nodes in Texas and on the West Coast as part of our phased ramp-up. Looking ahead, we continue to evaluate potential new sites and the possibility of self-build facilities."

Mr. Simon Tang, Chief Financial Officer of Cango, stated, "During the quarter, we recorded a net loss of US$81.6 million, mainly driven by non-cash impairment and disposal losses on our mining machines. During the quarter, we also launched a Bitcoin hedging program designed to manage our exposure to Bitcoin price volatility and enhance the predictability of operating cash flows. We intend to use hedging strictly as a risk management tool, not for speculative purposes. Related short-term positions are reflected on our balance sheet and will be adjusted as we continue to execute this program in a disciplined manner."

Second Quarter 2026 Financial Results from Continuing Operations

REVENUES

During the quarter, total revenues were US$50.8 million, including US$47.4 million from Bitcoin mining and US$3.4 million from other revenues. Compared with the first quarter of 2026, total revenue decreased approximately 50%, primarily reflecting the Company's proactive reduction of operating hashrate as it phased out older, less efficient S19 series mining machines and transitioned some capacity to a hosted leasing model. While this strategic adjustment temporarily impacted top-line revenue, it resulted in lower operating costs and an improved overall cash flow profile.

OPERATING COSTS AND EXPENSES

During the quarter, total operating costs and expenses were US$131.4 million. These costs were primarily associated with the Company's Bitcoin mining business and the recognition of impairment loss on mining machines, and included the loss from changes in fair value of crypto assets.

Cost of revenue (exclusive of depreciation shown below) was US$50.7 million, down from US$99.6 million in the first quarter of 2026. This was driven by lower electricity and hosting expenses following the hashrate reduction.

Depreciation was US$16.9 million, down from US$29.4 million in the first quarter of 2026.

General and administrative expenses, including related-party fees, totaled US$8.4 million.

Impairment loss from mining machines was US$42.9 million.

Loss on disposal of mining machines was US$8.5 million.

Loss from changes in fair value of crypto assets was US$4.1 million, compared to a US$151.8 million loss from changes in fair value of crypto assets in the first quarter of 2026. This change is primarily driven by the stabilization and modest recovery in Bitcoin market prices during the quarter and the initial impact of our newly launched Bitcoin hedging program.

LOSS FROM OPERATIONS

Loss from operations in the second quarter of 2026 was US$80.6 million, compared with an operating loss of US$254.4 million in the first quarter of 2026.

NET LOSS FROM CONTINUING OPERATIONS

Net loss from continuing operations in the second quarter of 2026 was US$81.6 million, compared with a net loss of US$261.1 million in the first quarter of 2026. The net loss was mainly driven by non-cash impairment and disposal losses.

ADJUSTED EBITDA

Adjusted EBITDA in the second quarter of 2026 was a loss of US$10.7 million, which included a US$4.1 million loss from changes in fair value of crypto assets, compared with a loss of US$154.1 million in the first quarter of 2026.

BALANCE SHEET

As of June 30, 2026, the Company held:

Cash and cash equivalents of US$10.1 million, compared with US$7.2 million as of March 31, 2026.

1,056 BTC in treasury holdings.

Mining machines with a net value of US$58.7 million.

Long-term debts (related party) of US$31.2 million, compared with US$30.6 million as of March 31, 2026.

Conference Call Information

The Company's management will hold a conference call on Monday, August 31, 2026, at 9:00 P.M.  Eastern Time to discuss the financial results. Listeners may access the call by dialing the following numbers:

International: 

+1-412-902-4272

United States Toll Free:

+1-888-346-8982

Mainland China Toll Free:

4001-201-203

Hong Kong, China Toll Free:

800-905-945

Conference ID: 

Cango Inc.

The replay will be accessible through September 6, 2026, by dialing the following numbers:

International: 

+1-412-317-0088

United States Toll Free:

+1-855-669-9658

Access Code:

8654407

A live and archived webcast of the conference call will also be available at the Company's investor relations website at http://ir.cangoonline.com.

About Cango Inc.

Cango Inc. (NYSE: CANG) is a Bitcoin mining company with a vision to establish an integrated, global infrastructure platform capable of powering the future digital economy. The Company's mining operations span across North America, the Middle East, South America, and East Africa.

Since entering the digital asset space in November 2024, Cango has activated pilot projects in both integrated energy solutions and distributed AI computing. In parallel, Cango continues to operate an online international used car export business through AutoCango.com.

For more information, please visit: www.cangoonline.com and follow us on: X and LinkedIn.

Use of Non-GAAP Financial Measure

As part of our review of business performance, we present adjusted EBITDA as non-GAAP financial measure to help assess our core operating results. Adjusted EBITDA is defined as net income or loss before interest, taxes, depreciation, and amortization, impairment, results from discontinued operations and further excludes share-based compensation expenses and other non-operating income and expenses. We believe adjusted EBITDA can be an important financial measure because it allows management, investors, and our board of directors to evaluate and compare our operating results, including our return on capital and operating efficiency from period-to-period by making such adjustments.

While adjusted EBITDA is not a measure defined under U.S. GAAP, management uses it to evaluate performance, make strategic decisions, and set operating plans. Management believes it also helps investors gain a clearer understanding of our underlying performance by excluding certain costs and expenses that management believes are not indicative of our core operating results. The presentation of these non-GAAP financial measures is not meant to be considered in isolation or as a substitute for results or guidance prepared and presented in accordance with U.S. GAAP.

The Company compensates for these limitations by reconciling the non-GAAP financial measure to the nearest U.S. GAAP performance measure, all of which should be considered when evaluating the Company's performance. The Company encourages you to review its financial information in its entirety and not rely on a single financial measure.

Reconciliations of Cango's non-GAAP financial measure to the most comparable U.S. GAAP measure are included at the end of this press release.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this announcement, contain forward-looking statements. Cango may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Cango's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Cango's goal and strategies; Cango's expansion plans; the development and commercialization of its AI infrastructure business; the performance and economics of its Bitcoin mining operations; Bitcoin price volatility; Cango's future business development, financial condition and results of operations; Cango's expectations regarding demand for, and market acceptance of, its solutions and services; general economic and business conditions; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in Cango's filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and Cango does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

CANGO INC.

UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in US dollar ("US$"), except for number of shares）

 As of December 31, 2025 

As of June 30, 2026

 US$ 

 US$ 

ASSETS:

Current assets:

Cash and cash equivalents

41,243,627

10,121,719

Crypto currencies

42,545

12,892,900

Accounts receivable, net

1,661,702

1,818,814

Accounts receivable, net - related parties

1,064,440

-

Prepayments and other current assets, net

6,835,599

54,208,544

Other current assets, net - related party

74,270,770

42,108,750

Total current assets

125,118,683

121,150,727

Non-current assets:

Mining machines, net

248,745,505

58,699,566

Property, plant and equipment, net

18,797,925

22,290,496

Intangible assets, net

292,836

277,744

Operating lease right-of-use assets, net

2,079,937

1,764,239

Receivable for bitcoin collateral, net - non-current - related party

662,968,814

61,485,537

Other non-current assets, net

68,025,983

21,761,273

Other non-current assets, net - related party

6,955,650

6,955,650

Total non-current assets

1,007,866,650

173,234,505

TOTAL ASSETS

1,132,985,333

294,385,232

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:

Short-term debts

-

8,032,711

Accrued expenses and other current liabilities

82,329,075

22,954,250

Accrued expenses and other current liabilities - related parties

5,025,566

1,184,368

Income tax payable

88,792,503

88,361,704

Short-term lease liabilities

573,959

559,170

Total current liabilities

176,721,103

121,092,203

Non-current liabilities:

Long-term debts - related party

557,567,671

31,227,904

Deferred tax liability

1

1

Long-term operating lease liabilities

1,655,272

1,336,517

Convertible Note

-

9,984,086

Total non-current liabilities

559,222,944

42,548,508

Total liabilities

735,944,047

163,640,711

Shareholders' equity

Ordinary shares

44,171

49,796

Treasury shares

(103,424,568)

(104,429,322)

Additional paid-in capital

1,135,958,943

1,213,346,273

Accumulated deficit

(635,537,260)

(978,222,226)

Total Cango Inc.'s  equity

397,041,286

130,744,521

Total shareholders' equity

397,041,286

130,744,521

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

1,132,985,333

294,385,232

CANGO INC.

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF

COMPREHENSIVE INCOME

(Amounts in US dollar ("US$"), except for number of shares)

 For three months ended June 30 

 For six months ended June 30 

2025

2026

2025

2026

 US$ 

 US$ 

 US$ 

 US$ 

Revenues

139,836,585

50,780,771

283,990,631

152,781,755

Bitcoin mining income

138,125,669

47,427,558

282,269,981

145,871,438

Other revenues

1,710,916

3,353,213

1,720,650

6,380,443

Other revenues from related parties

-

-

-

529,874

Operating cost and expenses:

Cost of revenue  (exclusive of depreciation shown below)

112,786,283

50,694,280

225,447,985

150,273,065

Cost of revenue  (depreciation)

21,849,482

16,930,355

43,194,326

46,302,554

General and administrative

2,986,487

7,788,237

13,014,756

14,337,583

General and administrative - related parties

-

647,653

-

1,295,306

Provision (Net recovery) for credit losses

920,228

(221,528)

1,209,459

(1,201,281)

Impairment loss from mining machines

256,856,570

42,861,871

256,856,570

91,900,419

(Gain) Loss on changes in fair value of crypto assets

(78,450,881)

4,148,957

(51,715,376)

155,987,387

Loss on disposal of mining machines

-

8,546,085

-

28,853,297

Total operation cost and expense

316,948,169

131,395,910

488,007,720

487,748,330

Loss from operations

(177,111,584)

(80,615,139)

(204,017,089)

(334,966,575)

Interest income

696,981

11

991,173

2,145

Interest expense

(2,053,009)

-

(3,363,606)

-

Interest expense - related party

-

(597,032)

-

(7,299,899)

Foreign exchange (loss) gain, net

19,702

120

(7,988)

(512)

Other income

114,123

-

226,993

-

Other expense

(78,095)

-

(78,095)

-

Net loss before income taxes

(178,411,882)

(81,212,040)

(206,248,612)

(342,264,841)

Income tax benefit (expenses)

1,581,658

(420,125)

1,150,475

(420,125)

Net loss from continuing operations 

(176,830,224)

(81,632,165)

(205,098,137)

(342,684,966)

Discontinued operations:

Loss from discontinued operations

(125,915,027)

-

(129,822,040)

-

Income tax expense

(32,646,978)

-

(32,646,978)

-

Net loss from discontinued operations

(158,562,005)

-

(162,469,018)

-

Net loss attributable to Cango Inc.'s shareholders

(335,392,229)

(81,632,165)

(367,567,155)

(342,684,966)

Losses per ordinary share:

Basic

Discontinued operations

(7.41)

-

(7.70)

-

Continuing operations 

(8.26)

(1.99)

(9.73)

(8.91)

Basic

(15.67)

(1.99)

(17.43)

(8.91)

Diluted

Discontinued operations

(7.41)

-

(7.70)

-

Continuing operations 

(8.26)

(1.99)

(9.73)

(8.91)

Diluted

(15.67)

(1.99)

(17.43)

(8.91)

Weighted average shares used to compute losses per ordinary share:

Basic

21,408,969

41,021,969

21,084,595

38,455,840

Diluted

21,408,969

41,021,969

21,084,595

38,455,840

Other comprehensive income, net of tax

Release accumulated other comprehensive loss

44,270,340

-

44,270,340

-

Foreign currency translation adjustment

10,583,883

-

5,304,633

-

Total comprehensive loss

(280,538,006)

(81,632,165)

(317,992,182)

(342,684,966)

Total comprehensive loss attributable to Cango Inc.'s shareholders

(280,538,006)

(81,632,165)

(317,992,182)

(342,684,966)

CANGO INC.

RECONCILIATIONS OF GAAP AND NON-GAAP RESULTS

(Amounts in US dollar ("US$")

 For three months ended June 30 

 For six months ended June 30 

2025

2026

2025

2026

 (Unaudited) 

 (Unaudited) 

 (Unaudited) 

 (Unaudited) 

 US$ 

 US$ 

 US$ 

 US$ 

Net loss

(335,392,229)

(81,632,165)

(367,567,155)

(342,684,966)

Less: Discontinued operations:

           Loss from discontinued operations

(125,915,027)

-

(129,822,040)

-

           Income tax expense

(32,646,978)

-

(32,646,978)

-

           Loss on discontinued operations

(158,562,005)

-

(162,469,018)

-

Net loss from continuing operations 

(176,830,224)

(81,632,165)

(205,098,137)

(342,684,966)

Add: Interest expense

2,053,009

597,032

3,363,606

7,299,899

Add: Income tax expenses (benefit)

(1,581,658)

420,125

(1,150,475)

420,125

Add: Depreciation

21,851,200

16,930,355

43,201,199

46,319,358

Cost of revenue

21,849,482

16,930,355

43,194,326

46,302,554

General and administrative

1,718

-

6,873

16,804

Add: Impairment loss from mining machines

256,856,570

42,861,871

256,856,570

91,900,419

Add: Loss on disposal of mining machines

-

8,546,085

-

28,853,297

Add: Other expenses

78,095

-

78,095

Less: Other income

114,123

-

226,993

-

Add: Share-based compensation expenses

152,674

1,553,214

3,697,862

3,089,509

General and administrative

152,674

1,553,214

3,697,862

3,089,509

Non-GAAP adjusted EBITDA

102,465,543

(10,723,483)

100,721,727

(164,802,359)

Non-GAAP adjusted EBITDA attributable to Cango Inc.'s shareholders

102,465,543

(10,723,483)

100,721,727

(164,802,359)

SOURCE Cango Inc.

21%

more press release views with 

Request a Demo

SiMa.ai and ARK Electronics Partner to Accelerate Intelligent, Autonomous Drones

NEWS PROVIDED BY

SiMa.ai

Aug 31, 2026, 17:00 ET

SHARE THIS ARTICLE

Production-ready joint solution to speed development and deployment of affordable, high-performance drones for UAS, industrial, and agriculture

SAN JOSE, Calif. and SALT LAKE CITY, Aug. 31, 2026 /PRNewswire/ -- SiMa.ai, a leader in Physical AI, and ARK Electronics, a designer and manufacturer of high-quality, made-in-the-USA drone and robotics electronics, today announced a strategic partnership to accelerate the deployment of next-generation autonomous drones. The companies are launching the ARK-SiMa.ai Modalix MLSoC Bundles – production-ready, affordable, high-performance solutions designed to simplify the development of intelligent drones for commercial and defense markets.

SiMa.ai x ARK Electronics

The SiMa.ai Physical AI platform combines hardware and software in one purpose-built offering: the Modalix System-on-Module (SoM), built on the Modalix MLSoC, and Palette Neat, an agentic development environment that compresses AI development from months to days. By pairing SiMa.ai's platform with ARK Electronics technology drones and robotics expertise, the partnership delivers a uniquely complete Physical AI foundation, priced for mass-market commercial, industrial, agriculture, and defense deployment at scale.

"The drone market is at an inflection point, and winning programs will be built on platforms that pair globally trusted hardware with best-in-class AI compute," said Durga Peddireddy, VP of Strategic Business Development and Partnerships, SiMa.ai. "With ARK Electronics, we are delivering the ecosystem a complete US-made, affordable solution for intelligent autonomy without compromising on performance or trust."

"Autonomous intelligence is the next frontier for drones across defense, agriculture, and commercial applications," said Alex Klimaj, CEO, ARK Electronics. "By building and validating this joint solution on SiMa.ai's Physical AI platform, we give our customers a purpose-built Physical AI foundation, with exceptional performance per watt and familiar form factors, so they can develop faster and deploy at scale."

The Modalix SoM is form-factor compatible with the industry's leading GPU-based edge platform. For the drone and robotics ecosystem, this compatibility accelerates development, de-risks design, and shortens time-to-market, while gaining higher performance, lower power, and lower cost in a best-in-class SWaP-C (Size, Weight, Power, and Cost) foundation. ARK Electronics is central to delivering this benefit, having built, validated, and brought the joint solutions to the drone ecosystem.

Availability

The ARK-SiMa.ai Modalix MLSoC Bundles are available today to qualified drone OEMs and system integrators at: https://go.sima.ai/ark-bundles.

About ARK Electronics

ARK Electronics is a provider of mission-critical, made-in-the-USA drone and robotics electronics, including NDAA-compliant, Blue UAS-listed flight controllers, GPS modules, sensors, and embedded computers for defense, commercial, and research applications. A Dronecode Foundation member and ArduPilot partner, ARK Electronics is committed to open standards and trusted, domestically manufactured hardware. Learn more at www.arkelectron.com.

About SiMa.ai

SiMa.ai is a leader in Physical AI, delivering a purpose-built, software-centric platform that brings best-in-class performance, power efficiency, and ease of use to Physical AI applications. The company is focused on scaling Physical AI across robotics, automotive, drones, industrial automation, aerospace and defense, smart vision, and healthcare. Learn more at www.sima.ai.

Media Contacts

SiMa.ai: publicrelations@sima.ai

Ark Electronics: marketing@arkelectron.com

SOURCE SiMa.ai

21%

more press release views with 

Request a Demo

USA Kidney and Transplant Experts In Little Rock September 10 to 13

NEWS PROVIDED BY

American Association of Kidney Patients

Aug 31, 2026, 16:56 ET

SHARE THIS ARTICLE

William J. Clinton Presidential Center Hosts Next Generation Care Talk

No Admission Fee to Learn More on Prevention, Transplants, and Treatments

WASHINGTON, Aug. 31, 2026 /PRNewswire/ -- The American Association of Kidney Patients (AAKP), the nation's oldest and largest fully independent kidney patient advocacy organization, will host its 51st annual National Patient Meeting September 10-13, 2026, in Little Rock, Arkansas. Event admission and meals are free to kidney patients, family members/care partners, and living organ donors; pre-registration is encouraged and can be completed online at https://bit.ly/AAKPNPM or by calling (800) 749-2257.

In 2011, AAKP hosted a groundbreaking discussion at the William J. Clinton Presidential Center that highlighted the direct link between outdated kidney dialysis care and patient unemployment, marking the first time a national kidney organization targeted greater innovation specifically to end economic dependency and increase patient survival.

The AAKP National Patient Meeting is the premier in-person and online kidney patient and care partner event. The program includes top healthcare and policy influencers, academic research experts, innovation leaders from top pharmaceutical, device, and diagnostic companies, and major nonprofit organizations. Prominently featured are University of Arkansas for Medical Sciences (UAMS) kidney experts Dr. John M. Arthur, Chief, Nephrology Division; Director, Translational Research Institute; and Director, Junior Faculty Mentored Research Program, Department of Internal Medicine, Nephrology at the University of Arkansas for Medical Sciences; Dr. Brandi P. Wright, Nephrologist, Jefferson Regional Medical Center; Medical Director, Lifepoint Health Systems; Associate Professor at the University of Arkansas for Medical Sciences; Dr. Manisha Singh, Professor; Director, Home Dialysis, UAMS and VA Little Rock; Co-Director Renal Module, Division of Nephrology, Department of Internal Medicine, at the University of Arkansas for Medical Sciences, and Joy Cope, MSN, MBA-HC, RN; Nursing Director and Administrator, Solid Organ Transplant Program, University of Arkansas for Medical Sciences.  Dr. Arthur will speak on Cardio Kidney Metabolic (CKM) Syndrome; Dr. Wright will speak on Cardio Kidney Metabolic (CKM) lab values; Dr. Singh will speak on rare kidney diseases; and Ms. Cope will discuss how kidney patients maintain transplant readiness and eligibility.

They are joined by more than 30 other experts, including internationally known science leaders Dr. Dominic Raj, the Bert B. Brooks Chair in the School of Medicine, Professor of Medicine, Biochemistry and Genetics, and Biostatistics and Epidemiology, and Director of the Division of Renal Disease and Hypertension at the George Washington University School of Medicine and Health Sciences (GW SMHS), and Dr. Prabir Roy-Chaudhury, the Drs. Ronald and Katherine Falk Eminent Professor in Nephrology and the Co-Director of the Kidney Center at the University of North Carolina (UNC). Drs. Raj and Roy-Chaudhury will discuss rapidly evolving kidney science and care innovations unfolding during what AAKP has termed the Decade of the Kidney™.

The AAKP National Patient Meeting begins Thursday, September 10, with AAKP's Public Policy Forum at the William J. Clinton Presidential Center from 1:00 p.m. – 4:00 p.m. CT. This complimentary, in-person event will highlight kidney research and innovation, as well as the impact of federal regulatory and reimbursement decisions. Doors open at 12:00 p.m. CT with lunch provided. Registration is required; please click here to reserve your spot.

The National Patient Meeting continues September 11 – 13 at the Little Rock Marriott. Click here for virtual registration, and here for in-person registration.  

Who:  The American Association of Kidney Patients (AAKP)

What: The 51st Annual National Patient Meeting

When: September 10-13, 2026

Where: 

Public Policy Forum, September 10th from 1:00 p.m. – 4:00 p.m. CT at the Clinton Presidential Library (free registration, complimentary lunch provided)

Kidney Patient Meeting, September 11 – 13 at the Little Rock Marriott, Little Rock, Arkansas, and virtually (free registration for virtual and in-person attendees, complimentary meals provided to in-person attendees)

Follow AAKP on social at @kidneypatient on Facebook, @kidneypatients on X, and @kidneypatients on Instagram. Visit http://www.aakp.org for more information on AAKP patient leadership and kidney care.

MEDIA CONTACT:

Brendan LaCivita

National and Medical Media Specialist

blacivita@aakp.org

(813) 906-7740

SOURCE American Association of Kidney Patients

21%

more press release views with 

Request a Demo

250 WEST 96TH STREET NAMES NEW SALES TEAM, BECOMES TOP PERFORMING NEW DEVELOPMENT IN MANHATTAN

NEWS PROVIDED BY

JVP Development

Aug 31, 2026, 15:04 ET

SHARE THIS ARTICLE

Corcoran's Team Arceon Joins JVP Development's Recently Completed Upper West Side Luxury Condominium and Makes it July's Best-Selling New Project, Now 65% Sold

NEW YORK, Aug. 31, 2026 /PRNewswire/ -- JVP Development has appointed Team Arceon, led by Corcoran Top 25 broker Kristen Suh, as the exclusive sales and marketing team for 250 West 96th Street, the 131-residence luxury condominium on Manhattan's Upper West Side designed by renowned Danish designer Thomas Juul-Hansen. The official announcement comes on the heels of 250 West 96th Street being recognized by Marketproof as Manhattan's top-performing new development in July 2026, with eight contracts signed during the month alone.

250 West 96th Street

Kristen Suh

"We brought on Kristen Suh and Team Arceon because we knew they had the experience and market expertise to accelerate sales, and they've delivered exactly that," said Van Nguyen, Founder of JVP Development. "Their strategic approach and execution have helped to make 250 West 96th Street Manhattan's top-performing new development in July, and we're confident they'll continue building on that momentum as we move toward a successful sellout."

Since its launch, Team Arceon has led the successful sellout of Oosten, one of Williamsburg's most notable waterfront condominium developments, and currently represents sales at both 250 West 96th Street and Sutton Tower. Combined, the team's active and completed development portfolio represents more than $1 billion in total sellout value.

"The strong response we've seen at 250 West 96th Street reflects what today's luxury buyers are looking for: exceptional design, enduring quality, and a product that truly stands apart," said Kristen Suh, Founder of Team Arceon at Corcoran. "JVP Development and Thomas Juul-Hansen have created an extraordinary residential offering where every detail, from the architecture and residences to the amenity spaces, has been executed at the highest level. Buyers recognize that quality, and we're excited to continue building on the property's momentum."

250 West 96th Street is a refined contemporary interpretation of classic Upper West Side architecture. Clad in Jura gray limestone with expansive bronze-framed windows, the building reimagines the scale, proportions, and materiality of the neighborhood's most distinguished residences through a distinctly modern lens. The condominium features an exceptional collection of one- to five-bedroom residences characterized by generous layouts, abundant natural light, and meticulously crafted interiors. Residents enjoy an extensive suite of wellness, recreation, and entertainment amenities, including a 75-foot indoor saltwater pool, spa suite, fitness center, Pilates studio, regulation squash/half basketball court, children's playroom, music room, entertainment lounge, pet grooming station, and a landscaped rooftop terrace complete with a rare outdoor cinema and sweeping views of the Manhattan skyline and Hudson River.

Ideally situated between Riverside Park and Central Park, 250 West 96th Street offers the quintessential Upper West Side lifestyle, placing residents moments from the neighborhood's acclaimed restaurants, cultural institutions, boutique shopping, and iconic green spaces. The property also offers immediate access to the 96th Street 1/2/3 subway station, providing seamless connectivity throughout Manhattan and beyond.

For more information or to arrange a showing, please contact Team Arceon at Corcoran at 646.640.6185, email info@250west96th.com, or visit 250west96th.com.

About JVP Development

JVP Development is a private real estate firm based in New York, Florida and Texas with more than $5BN in properties owned and in development throughout the United States. While guided by broader macroeconomics and demographics, we invest in specific assets and locations based on exhaustive due diligence and analysis to structure the best risk-adjusted return profiles. As owners and landlords, JVP believes that quality of product leads to quality of results. With extensive construction, operating and asset management experience, JVP can look across real estate assets and strategies to acquire and manage, develop and build, or capitalize and lend to the most compelling opportunities.

About Team Arceon at Corcoran 

Founded and led by Corcoran Top 25 broker Kristen Suh, Team Arceon at Corcoran is a New York City-based real estate sales and advisory team specializing in luxury new development, sponsor representation, and sophisticated buyer advisory services. With a focus on strategy, analysis, and long-term value, the team brings institutional precision to offering plan analysis, unit selection, pricing strategy, and complex multi-unit transactions, paired with the discretion of a boutique consultancy. Team Arceon led the successful sellout of Oosten, one of Williamsburg's most notable waterfront condominium developments, and currently represents sales at Sutton Tower and 250 West 96th Street. Its active and completed development portfolio represents more than $1 billion in total sellout value.

SOURCE JVP Development

21%

more press release views with 

Request a Demo